These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 24823954)

  • 1. Left ventricular reverse remodeling, device-related adverse events, and long-term outcome after cardiac resynchronization therapy in the elderly.
    Höke U; Putter H; Van Der Velde ET; Schalij MJ; Delgado V; Bax JJ; Marsan NA
    Circ Cardiovasc Qual Outcomes; 2014 May; 7(3):437-44. PubMed ID: 24823954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implantable defibrillators improve survival in patients with mildly symptomatic heart failure receiving cardiac resynchronization therapy: analysis of the long-term follow-up of remodeling in systolic left ventricular dysfunction (REVERSE).
    Gold MR; Daubert JC; Abraham WT; Hassager C; Dinerman JL; Hudnall JH; Cerkvenik J; Linde C
    Circ Arrhythm Electrophysiol; 2013 Dec; 6(6):1163-8. PubMed ID: 24125796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term impact of cardiac resynchronization therapy in mild heart failure: 5-year results from the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study.
    Linde C; Gold MR; Abraham WT; St John Sutton M; Ghio S; Cerkvenik J; Daubert C;
    Eur Heart J; 2013 Sep; 34(33):2592-9. PubMed ID: 23641006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial.
    Daubert C; Gold MR; Abraham WT; Ghio S; Hassager C; Goode G; Szili-Török T; Linde C;
    J Am Coll Cardiol; 2009 Nov; 54(20):1837-46. PubMed ID: 19800193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rethinking cardiac resynchronization therapy: the impact of ventricular dyssynchrony on outcome.
    Prinz C; Felice CD; Lehmann R; Schwarz M; Prinz EM; Bitter T; Vogt J; Lamp B; Faber L; Horstkotte D
    Int J Cardiol; 2013 Oct; 168(4):3932-9. PubMed ID: 23870640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic benefit of optimum left ventricular lead position in cardiac resynchronization therapy: follow-up of the TARGET Study Cohort (Targeted Left Ventricular Lead Placement to guide Cardiac Resynchronization Therapy).
    Kydd AC; Khan FZ; Watson WD; Pugh PJ; Virdee MS; Dutka DP
    JACC Heart Fail; 2014 Jun; 2(3):205-12. PubMed ID: 24952685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term reverse remodeling with cardiac resynchronization therapy: results of extended echocardiographic follow-up.
    Verhaert D; Grimm RA; Puntawangkoon C; Wolski K; De S; Wilkoff BL; Starling RC; Tang WH; Thomas JD; Popović ZB
    J Am Coll Cardiol; 2010 Apr; 55(17):1788-95. PubMed ID: 20413027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiac resynchronization therapy improves ejection fraction and cardiac remodelling regardless of patients' age.
    Brambatti M; Guerra F; Matassini MV; Cipolletta L; Barbarossa A; Urbinati A; Marchesini M; Capucci A
    Europace; 2013 May; 15(5):704-10. PubMed ID: 23385052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-capillary pulmonary hypertension and right ventricular dilation predict clinical outcome in cardiac resynchronization therapy.
    Chatterjee NA; Upadhyay GA; Singal G; Parks KA; Dec GW; Singh JP; Lewis GD
    JACC Heart Fail; 2014 Jun; 2(3):230-7. PubMed ID: 24952689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival with cardiac-resynchronization therapy in mild heart failure.
    Goldenberg I; Kutyifa V; Klein HU; Cannom DS; Brown MW; Dan A; Daubert JP; Estes NA; Foster E; Greenberg H; Kautzner J; Klempfner R; Kuniss M; Merkely B; Pfeffer MA; Quesada A; Viskin S; McNitt S; Polonsky B; Ghanem A; Solomon SD; Wilber D; Zareba W; Moss AJ
    N Engl J Med; 2014 May; 370(18):1694-701. PubMed ID: 24678999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Device-measured physical activity versus six-minute walk test as a predictor of reverse remodeling and outcome after cardiac resynchronization therapy for heart failure.
    Vegh EM; Kandala J; Orencole M; Upadhyay GA; Sharma A; Miller A; Merkely B; Parks KA; Singh JP
    Am J Cardiol; 2014 May; 113(9):1523-8. PubMed ID: 24641966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of cardiac resynchronization therapy in patients with asymptomatic to mild heart failure: insights from the European cohort of the REVERSE (Resynchronization Reverses remodeling in Systolic Left Ventricular Dysfunction).
    Linde C; Mealing S; Hawkins N; Eaton J; Brown B; Daubert JC;
    Eur Heart J; 2011 Jul; 32(13):1631-9. PubMed ID: 21112898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term prognosis after cardiac resynchronization therapy is related to the extent of left ventricular reverse remodeling at midterm follow-up.
    Ypenburg C; van Bommel RJ; Borleffs CJ; Bleeker GB; Boersma E; Schalij MJ; Bax JJ
    J Am Coll Cardiol; 2009 Feb; 53(6):483-90. PubMed ID: 19195605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of renal insufficiency on long-term clinical outcome in patients with heart failure treated by cardiac resynchronization therapy.
    Hosoda J; Ishikawa T; Matsushita K; Matsumoto K; Kimura Y; Miyamoto M; Ogawa H; Takamura T; Sugano T; Ishigami T; Uchino K; Kimura K; Umemura S
    J Cardiol; 2012 Oct; 60(4):301-5. PubMed ID: 22763383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Left ventricular reverse remodelling, long-term clinical outcome, and mode of death after cardiac resynchronization therapy.
    Foley PW; Chalil S; Khadjooi K; Irwin N; Smith RE; Leyva F
    Eur J Heart Fail; 2011 Jan; 13(1):43-51. PubMed ID: 21051462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Revisiting diastolic filling time as mechanistic insight for response to cardiac resynchronization therapy.
    Verbrugge FH; Verhaert D; Grieten L; Dupont M; Rivero-Ayerza M; De Vusser P; Van Herendael H; Reyskens R; Vandervoort P; Tang WH; Mullens W
    Europace; 2013 Dec; 15(12):1747-56. PubMed ID: 23821473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Left ventricular discoordination index measured by speckle tracking strain rate imaging predicts reverse remodelling and survival after cardiac resynchronization therapy.
    Wang CL; Powell BD; Redfield MM; Miyazaki C; Fine NM; Olson LJ; Cha YM; Espinosa RE; Hayes DL; Hodge DO; Lin G; Friedman PA; Oh JK
    Eur J Heart Fail; 2012 May; 14(5):517-25. PubMed ID: 22411692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac resynchronization therapy-defibrillator improves long-term survival compared with cardiac resynchronization therapy-pacemaker in patients with a class IA indication for cardiac resynchronization therapy: data from the Contak Italian Registry.
    Morani G; Gasparini M; Zanon F; Casali E; Spotti A; Reggiani A; Bertaglia E; Solimene F; Molon G; Accogli M; Tommasi C; Paoletti Perini A; Ciardiello C; Padeletti L
    Europace; 2013 Sep; 15(9):1273-9. PubMed ID: 23439866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of long-term resynchronization therapy on left ventricular remodeling in pacemaker patients upgraded to biventricular devices.
    Vatankulu MA; Goktekin O; Kaya MG; Ayhan S; Kucukdurmaz Z; Sutton R; Henein M
    Am J Cardiol; 2009 May; 103(9):1280-4. PubMed ID: 19406272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of ejection fraction on the clinical response to cardiac resynchronization therapy in mild heart failure.
    Linde C; Daubert C; Abraham WT; St John Sutton M; Ghio S; Hassager C; Herre JM; Bergemann TL; Gold MR;
    Circ Heart Fail; 2013 Nov; 6(6):1180-9. PubMed ID: 24014828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.